These include anti-CCR4 CAR-T cells, which have proven to be effective against several T-cell malignancies and small-molecule CCR4 antagonists capable of improving the efficacy of anti-cancer vaccines by preventing Treg induction [103,104]. This evidence concerns the gene CCR4 and cancer.